Breaking News Instant updates and real-time market news.

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

19:36
05/20/19
05/20
19:36
05/20/19
19:36

Ocular Therapeutix price target lowered to $8 from $13 at Piper Jaffray

Piper Jaffray analyst Joseph Catanzaro lowered his price target on Ocular Therapeutix to $8 after disclosing that its OTX-TP Phase 3 glaucoma trial had failed, even though the analyst believes that the "clinical meaningfulness" of its intraocular pressure reduction "will be debated." Catanzaro notes that the company intends to further discuss its data with the FDA, but acknowledges that its revenue outlook may be at risk on today's disclosure. The analyst is also keeping his Overweight rating for the time being, further stating that the company will likely perform subgroup analyses, with additional trial likely requested by the FDA if the new set of data is "clinically meaningful."

  • 11

    Jun

  • 10

    Nov

OCUL Ocular Therapeutix
$3.36

-0.1 (-2.89%)

12/04/18
HCWC
12/04/18
NO CHANGE
Target $12
HCWC
Buy
Ocular Therapeutix price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Ocular Therapeutix to $12 after the FDA approved Dextenza for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. The analyst believes the news should bolster confidence in the company among investors. The approval not only validates Ocular's hydrogel drug delivery platform, but endorses the incumbent management team's execution and accountability, Selvaraju tells investors in a research note. He reiterates a Buy rating on the name.
01/04/19
PIPR
01/04/19
NO CHANGE
Target $14
PIPR
Overweight
Piper sees 'significant share appreciation' potential for Ocular Therapeutix
Ocular Therapeutix expects top-line data from OTX-TP's first Phase III glaucoma study in the first half of 2019, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes investors have discounted this program based on mixed Phase I/II data that utilized different formulations and study designs. However, he thinks the Phase III design gives OTX-TP the best chance at demonstrating clinical efficacy in this setting. A successful outcome will be statistically significant IOP-reductions over placebo at all time points and importantly, at least a 5 mm Hg reduction in IOP from baseline at 6 of the 9 time points, Catanzaro contends, citing his review of literature and a survey of ophthalmologists. He believes such an outcome would represent "another successful application of the hydrogel platform and drive significant share appreciation." The analyst has an Overweight rating on Ocular Therapeutix with a $14 price target.
03/08/19
PIPR
03/08/19
NO CHANGE
Target $14
PIPR
Overweight
Ocular undervalued ahead of glaucoma data, says Piper Jaffray
Ahead of Dextenza's planned mid-2019 U.S. launch for post-cataract pain, Ocular Therapeutix is expected to report data from both OTX-TP and OTX-TIC in glaucoma are expected in first half of 2019, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. Now funded into 2020, Ocular shares remain undervalued for its suite of hydrogel-based products for both the front and back of the eye, Catanzaro contends. He maintains an Overweight rating on the shares with a $14 price target.
03/28/19
PIPR
03/28/19
NO CHANGE
Target $14
PIPR
Overweight
Ocular Therapeutix's Dextenza may provide substantial upside, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $14 price target on Ocular Therapeutix after its R&D day highlighting the company's preparations for a mid-2019 Dextenza launch as well as the overall breadth of the hydrogel platform. The analyst believes that while Dextenza gives Ocular Therapeutix a "nice foundation", the company also has "opportunities to expand in post-ophthalmic surgery, glaucoma, dry eye, retinal disease, as well as sinusitis,osteoarthritis and post-op incisional pain." Catanzaro speculates that Ocular Therapeutix could file up to 4 Investigational New Drug submissions per year.

TODAY'S FREE FLY STORIES

BAC

Bank of America

$27.93

-0.1 (-0.36%)

16:35
06/17/19
06/17
16:35
06/17/19
16:35
Upgrade
Bank of America rating change  »

Bank of America upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 06

    Aug

CYAD

Celyad

$13.50

-5.28 (-28.12%)

16:35
06/17/19
06/17
16:35
06/17/19
16:35
Hot Stocks
Celyad presents clinical update for CYAD-01 trials »

Celyad announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CINR

Ciner Resources

$18.87

-0.28 (-1.46%)

16:35
06/17/19
06/17
16:35
06/17/19
16:35
Hot Stocks
Ciner Resource Partners CEO Kirk Milling resigns »

On June 17, Ciner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBAYF

Hudson's Bay

$0.00

(0.00%)

16:34
06/17/19
06/17
16:34
06/17/19
16:34
Hot Stocks
Hudson's Bay CFO to take medical leave of absence »

HBC announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARRY

Array BioPharma

$46.42

16.83 (56.88%)

16:34
06/17/19
06/17
16:34
06/17/19
16:34
Recommendations
Array BioPharma analyst commentary  »

Array BioPharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNTR

Venator Materials

$4.93

-0.165 (-3.24%)

16:33
06/17/19
06/17
16:33
06/17/19
16:33
Hot Stocks
Venator Materials responds to Tronox answer, counterclaims »

Venator Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

16:32
06/17/19
06/17
16:32
06/17/19
16:32
Hot Stocks
MoneyGram enters strategic partnership with Ripple »

MoneyGram announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

CAAP

Corporacion America Airport

$7.97

0.24 (3.10%)

16:32
06/17/19
06/17
16:32
06/17/19
16:32
Hot Stocks
Corporacion America Airport reports May traffic up 3.3% y/y »

Total passenger traffic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$32.71

-0.3 (-0.91%)

16:32
06/17/19
06/17
16:32
06/17/19
16:32
Hot Stocks
Synovus increases share repurchase authorization to $725M »

Synovus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

HCHC

HC2 Holdings

$2.51

0.06 (2.45%)

16:31
06/17/19
06/17
16:31
06/17/19
16:31
Hot Stocks
HC2 Holdings company American Natural Gas acquires ampCNG for $41M »

HC2 Holdings, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
06/17/19
06/17
16:30
06/17/19
16:30
Options
Preliminary option volume of 14.6M today »

Preliminary option volume…

SRNE

Sorrento Therapeutics

$3.63

0.49 (15.61%)

16:30
06/17/19
06/17
16:30
06/17/19
16:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
06/17/19
06/17
16:30
06/17/19
16:30
General news
Treasury capital data showed inflows of $46.9 B in long term U.S. assets in April »

Treasury capital data…

ASLN

Aslan Pharmaceuticals

$3.32

-0.23 (-6.48%)

16:27
06/17/19
06/17
16:27
06/17/19
16:27
Syndicate
Aslan Pharmaceuticals files to sell $17.34M of ADSs »

ASLAN Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$72.22

0.65 (0.91%)

16:25
06/17/19
06/17
16:25
06/17/19
16:25
Hot Stocks
Square dismisses KPMG as auditor, engages Ernst & Young »

Square disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 27

    Jun

  • 01

    Aug

SNDK

Bought by WDC

$0.00

(0.00%)

, WDC

Western Digital

$36.26

-0.07 (-0.19%)

16:22
06/17/19
06/17
16:22
06/17/19
16:22
Hot Stocks
Nvidia names Donald Robertson as Chief Accounting Officer »

Nvidia (NVDA) announced…

SNDK

Bought by WDC

$0.00

(0.00%)

WDC

Western Digital

$36.26

-0.07 (-0.19%)

NVDA

Nvidia

$144.98

0.39 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 15

    Aug

CINR

Ciner Resources

$18.87

-0.28 (-1.46%)

16:22
06/17/19
06/17
16:22
06/17/19
16:22
Hot Stocks
Ciner Resources CEO Kirk Milling to resign »

Ciner Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACMR

ACM Research

$16.68

-0.57 (-3.30%)

16:22
06/17/19
06/17
16:22
06/17/19
16:22
Hot Stocks
ACM Research subsidiary executes agreements to prepare for STAR Market listing »

ACM Research announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

LTXB

LegacyTexas Financial

$38.91

0.69 (1.81%)

16:22
06/17/19
06/17
16:22
06/17/19
16:22
Downgrade
LegacyTexas Financial rating change  »

LegacyTexas Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 26

    Aug

SQ

Square

$72.22

0.65 (0.91%)

16:21
06/17/19
06/17
16:21
06/17/19
16:21
Hot Stocks
Breaking Hot Stocks news story on Square »

Square dismisses KPMG as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 27

    Jun

  • 01

    Aug

PFE

Pfizer

$42.87

0.12 (0.28%)

, ARRY

Array BioPharma

$46.42

16.83 (56.88%)

16:21
06/17/19
06/17
16:21
06/17/19
16:21
On The Fly
Fly Intel: Wall Street's top stories for Monday »

Stocks drifted higher for…

PFE

Pfizer

$42.87

0.12 (0.28%)

ARRY

Array BioPharma

$46.42

16.83 (56.88%)

BID

Sotheby's

$56.13

20.735 (58.59%)

CJ

C&J Energy Services

$12.88

2.15 (20.05%)

FRAC

Keane Group

$7.49

0.495 (7.08%)

GM

General Motors

$36.13

0.47 (1.32%)

BA

Boeing

$354.90

7.71 (2.22%)

ARQL

ArQule

$9.56

1.39 (17.01%)

PAYS

Paysign

$11.32

-1.38 (-10.87%)

AHT

Ashford Hospitality

$3.50

-0.15 (-4.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 09

    Jul

  • 01

    Aug

  • 12

    Aug

  • 28

    Aug

  • 16

    Sep

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
06/17/19
06/17
16:20
06/17/19
16:20
Options
Closing CBOE SPX and VIX Index summary for June 17th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$15.85

0.05 (0.32%)

16:19
06/17/19
06/17
16:19
06/17/19
16:19
Hot Stocks
EQT Corporation sees Q2 sales volumes 'at high end of guidance range' »

EQT Corporation provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

EIGR

Eiger BioPharmaceuticals

$10.49

0.35 (3.45%)

16:18
06/17/19
06/17
16:18
06/17/19
16:18
Hot Stocks
Eiger BioPharmaceuticals: Breakthrough Therapy Designation granted for avexitide »

Eiger BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLT

Poly

$43.05

-1.61 (-3.61%)

16:17
06/17/19
06/17
16:17
06/17/19
16:17
Conference/Events
Poly participates in an investor webinar with Northland Capital Markets »

Northland Capital Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Jun

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.